Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation

被引：30

作者：

Yong, ASM ^{[1
]}

Goldman, JM ^{[1
]}

机构：

[1] Hammersmith Hosp, Imperial Coll, Sch Med, Dept Haematol, London W12 0NN, England

来源：

BONE MARROW TRANSPLANTATION | 1999年 / 23卷 / 08期

关键词：

late relapse; chronic myeloid leukaemia; bone marrow transplantation;

D O I：

10.1038/sj.bmt.1701729

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Allogeneic bone marrow transplantation (BMT) is the treatment of choice for patients with chronic myeloid leukaemia (CML) who are relatively young and have suitable donors. Relapse is rare more than 5 years after allografting. We describe a patient who relapsed with myeloid blast transformation 14 years after allografting. This case suggests that leukaemia stem cells may on occasion remain quiescent for long periods and emphasises the importance of long-term follow-up after transplantation for CML.

引用

页码：827 / 828

页数：2

共 8 条

[1] RELAPSE INTO BLAST CRISIS FOLLOWING BONE-MARROW TRANSPLANTATION FOR CHRONIC PHASE CHRONIC MYELOID-LEUKEMIA - A REPORT OF 5 CASES [J].

CULLIS, JO ;

MARKS, DI ;

SCHWARER, AP ;

BARRETT, AJ ;

HOWS, JM ;

SWIRSKY, DM ;

GOLDMAN, JM .

BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (03) :378-382

[2] Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation [J].

Dermime, S ;

Mavroudis, D ;

Jiang, YZ ;

Hensel, N ;

Molldrem, J ;

Barrett, AJ .

BONE MARROW TRANSPLANTATION, 1997, 19 (10) :989-999

[3]

GRATWOHL A, 1993, BONE MARROW TRANSPL, V12, P509

[4] Relapsed chronic myeloid leukemia in accelerated phase 10 years after allogeneic bone marrow transplantation: full chimera reconversion with donor peripheral blood stem cells infusion [J].

Guimaraes, A ;

Machado, A ;

Carvalho, S ;

Alaiz, H ;

Vieira, L ;

Abecasis, M .

BONE MARROW TRANSPLANTATION, 1998, 22 (06) :595-597

[5] HLA-IDENTICAL SIBLING DONOR BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA IN 1ST CHRONIC PHASE - INFLUENCE OF GVHD PROPHYLAXIS ON OUTCOME [J].

MARKS, DI ;

HUGHES, TP ;

SZYDLO, R ;

KELLY, S ;

CULLIS, JO ;

SCHWARER, AP ;

MACKINNON, S ;

APPERLEY, J ;

BARRETT, AJ ;

HOWS, JM ;

GOLDMAN, JM .

BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (03) :383-390

[6] MARROW TRANSPLANTATION FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA [J].

THOMAS, ED ;

CLIFT, RA ;

FEFER, A ;

APPELBAUM, FR ;

BEATTY, P ;

BENSINGER, WI ;

BUCKNER, CD ;

CHEEVER, MA ;

DEEG, HJ ;

DONEY, K ;

FLOURNOY, N ;

GREENBERG, P ;

HANSEN, JA ;

MARTIN, P ;

MCGUFFIN, R ;

RAMBERG, R ;

SANDERS, JE ;

SINGER, J ;

STEWART, P ;

STORB, R ;

SULLIVAN, K ;

WEIDEN, PL ;

WITHERSPOON, R .

ANNALS OF INTERNAL MEDICINE, 1986, 104 (02) :155-163

[7] Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation [J].

vanRhee, F ;

Szydlo, RM ;

Hermans, J ;

Devergie, A ;

Frassoni, F ;

Arcese, W ;

deWitte, T ;

Kolb, HJ ;

Niederwiser, D ;

Jacobsen, N ;

Gahrton, G ;

Bandini, G ;

Carreras, E ;

Bacigalupo, A ;

Michallet, M ;

Ruutu, T ;

Reiffers, J ;

Goldman, JM ;

Apperley, J ;

Gratwohl, A .

BONE MARROW TRANSPLANTATION, 1997, 20 (07) :553-560

[8]

VANRHEE F, 1994, BONE MARROW TRANSPL, V14, P609

← 1 →